Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Cantor Fitzgerald
McKinsey
Deloitte
Cipla

Generated: August 25, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,576,053

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,576,053
Title:Methods and compositions for treating degenerative bone disorders
Abstract: The present disclosure provides methods and compositions using Syk inhibitory compounds for treating degenerative bone disorders and as prophylactic treatment to prevent bone loss. These treatments may reduce the fracture risk associated with bone loss and compromised bone strength.
Inventor(s): Masuda; Esteban (Menlo Park, CA), Pine; Polly (Los Altos, CA)
Assignee: Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:11/452,767
Patent Claims:1. A method of treating a degenerative bone disorder, comprising: administering to a subject in need thereof an amount of a Syk inhibitory compound effective to reduce bone loss, wherein the degenerative bone disorder is not associated with an autoimmune disease.

2. The method of claim 1 in which the Syk inhibitory compound is a 2,4-pyrimidinediamine compound.

3. The method of claim 1 in which the degenerative bone disorder is primary osteoporosis.

4. The method of claim 3 in which the primary osteoporosis is selected from the group consisting of postmenopausal osteoporosis, senile osteoporosis, and juvenile osteoporosis.

5. The method of claim 1 in which the degenerative bone disorder is associated with an endocrinopathy.

6. The method of claim 5 in which the endocrinopathy is selected from the group consisting of hypercorticolism, hypogonadism, hyperparathyroidism, and hypoparathyroidism.

7. The method of claim 1 in which the degenerative bone disorder is osteodystrophy.

8. The method of claim 1 in which the degenerative bone disorder is osteopenia.

9. The method of claim 1 in which the degenerative bone disorder is caused by an imbalance of osteoclast and osteoblast activity that results in net excess of bone resorption over bone formation.

10. The method of claim 1 further comprising adjunctively administering an antiresorptive agent.

11. The method of claim 10 in which the antiresorptive agent is selected from the group consisting of bisphosphonates; calcitonin; estrogen and selective estrogen receptor modulators (SERM).

12. The method of claim 1, further comprising adjunctively administering an osteoanabolic agent.

13. The method of claim 12 in which the osteoanabolic agent is selected from the group consisting of parathyroid hormone, strontium renelate, and growth hormone (GH).

14. A method of inhibiting loss of bone, comprising: administering to a subject an amount of a Syk inhibitory compound and a bone modulating agent.

15. The method of claim 14 in which the Syk inhibitory compound is a 2,4-pyrimidinediamine compound.

16. The method of claim 14 in which the bone modulating agent is an antiresorptive agent.

17. The method of claim 16 in which the antiresorptive agent is selected from the group consisting of bisphosphonates, calcitonin, estrogen and selective estrogen receptor modulators (SERM).

18. The method of claim 14 in which the bone modulating agent is an osteoanabolic agent.

19. The method of claim 18 in which the osteoanabolic agent is selected from the group consisting of parathyroid hormone, strontium renelate, and growth hormone (GH).

20. The method of claim 14 in which the subject is a menopausal or postmenopausal human female.

21. The method of claim 14 in which the subject is a human female with an estrogen deficiency.

22. The method of claim 14 in which the Syk inhibitory compound impairs the osteoclastogenesis that leads to a net excess of bone resorption over bone formation.

23. A composition comprising: a Syk inhibitory compound and a bone modulating agent.

24. The composition of claim 23 in which the Syk inhibitory compound is a 2,4-pyrimidinediamine compound.

25. The composition of claim 23 in which the bone modulating agent is an antiresorptive agent.

26. The composition of claim 25 in which the antiresorptive agent is selected from the group consisting of bisphosphonates, calcitonin, estrogen and selective estrogen receptor modulators (SERM).

27. The composition of claim 23 in which the bone modulating agent is an osteoanabolic agent.

28. The composition of claim 27 in which the osteoanabolic agent is selected from the group consisting of parathyroid hormone, strontium renelate; and growth hormone (GH).

29. The method of claim 10 in which the antiresorptive agent is selected from the group consisting of human calcitonin, salmon calcitonin, rat calcitonin, pig calcitonin, chicken calcitonin, 17.beta.-estradiol, conjugated equine estrogen (CEE), and C-21 progestins.

30. The method of claim 11 wherein the bisphosphonate is alendronate.

31. The composition of claim 26 wherein the bisphosphonate is alendronate.

Details for Patent 7,576,053

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Try a Free Trial Rigel Pharmaceuticals, Inc. (South San Francisco, CA) 2025-06-13 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Try a Free Trial Rigel Pharmaceuticals, Inc. (South San Francisco, CA) 2025-06-13 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Try a Free Trial Rigel Pharmaceuticals, Inc. (South San Francisco, CA) 2025-06-13 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   Try a Free Trial Rigel Pharmaceuticals, Inc. (South San Francisco, CA) 2025-06-13 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 7,576,053

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2006135915 Dec 21, 2006
World Intellectual Property Organization (WIPO) 2006135915 Mar 08, 2007
United States of America 2007004626 Jan 04, 2007
Japan 2008543855 Dec 04, 2008
Japan 2013231064 Nov 14, 2013
European Patent Office 1896134 Mar 12, 2008
Canada 2607901 Aug 16, 2016
>Country >Patent Number >Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Colorcon
Harvard Business School
UBS
Fuji
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.